Tipranavir
- Generic Name
- Tipranavir
- Brand Names
- Aptivus
- Drug Type
- Small Molecule
- Chemical Formula
- C31H33F3N2O5S
- CAS Number
- 174484-41-4
- Unique Ingredient Identifier
- ZZT404XD09
- Background
Tipranavir is a sulfonamide-containing dyhydropyrone and a nonpeptidic protease inhibitor that targets the HIV protease. Tipranavir and ritonavir are coadministered to treat HIV.
- Indication
For combination antiretroviral treatment of HIV-1 infected adult patients with evidence of viral replication, who are highly treatment-experienced or have HIV-1 strains resistant to multiple protease inhibitors.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
Tipranavir/Ritonavir Low Dose Pharmacokinetics in Treatment Naive Patients
- Conditions
- HIV Infections
- First Posted Date
- 2007-09-18
- Last Posted Date
- 2014-06-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 85
- Registration Number
- NCT00530920
- Locations
- 🇮🇹
1182.107.39001 Boehringer Ingelheim Investigational Site, Antella (fi), Italy
🇪🇸1182.107.34001 Boehringer Ingelheim Investigational Site, Barcelona, Spain
🇪🇸1182.107.34002 Boehringer Ingelheim Investigational Site, Barcelona, Spain
Observational Non-interventional Study (Anwendungsbeobachtung) With Aptivus® (Tipranavir) in HIV-infected Patients.
- First Posted Date
- 2007-09-18
- Last Posted Date
- 2014-04-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 65
- Registration Number
- NCT00531206
- Locations
- 🇩🇪
Boehringer Ingelheim Investigational Site, Wuppertal, Germany
Comparison of TPV/r to DRV/r in Triple Class Experienced Patient With Resistance to > 1 PI
- Conditions
- HIV Infections
- First Posted Date
- 2007-08-16
- Last Posted Date
- 2014-05-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 40
- Registration Number
- NCT00517192
- Locations
- 🇨🇦
1182.71.1002 Boehringer Ingelheim Investigational Site, Vancouver, British Columbia, Canada
🇧🇸1182.71.1016 Boehringer Ingelheim Investigational Site, Nassau, Bahamas
🇵🇹1182.71.3502 Boehringer Ingelheim Investigational Site, Amadora, Portugal
Safety and Antiviral Activity of TPV in HCV and/or HBV HIV Coinfected Patients TDM Randomised Pilot Evaluation
- Conditions
- HIV Infections
- First Posted Date
- 2007-03-15
- Last Posted Date
- 2014-05-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 11
- Registration Number
- NCT00447902
- Locations
- 🇺🇸
1182.99.31 Boehringer Ingelheim Investigational Site, Fort Lauderdale, Florida, United States
🇫🇷1182.99.3306K Boehringer Ingelheim Investigational Site, Nantes, France
🇩🇪1182.99.4909 Boehringer Ingelheim Investigational Site, Düsseldorf, Germany
SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoC
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2007-02-27
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 33
- Registration Number
- NCT00440271
- Locations
- 🇺🇸
1182.98.018 Boehringer Ingelheim Investigational Site, Clearwater, Florida, United States
🇺🇸1182.98.014 Boehringer Ingelheim Investigational Site, Fort Lauderdale, Florida, United States
🇺🇸1182.98.004 Boehringer Ingelheim Investigational Site, Decatur, Georgia, United States
3 TPV/RTV Doses in Multiple ARV Experienced Patients - Tipranavir Dose Defining Study
- Conditions
- HIV Infections
- First Posted Date
- 2006-01-12
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 216
- Registration Number
- NCT00275444
- Locations
- 🇺🇸
Mercer University School of Medicine, Macon, Georgia, United States
🇺🇸John's Hopkins University, Baltimore, Maryland, United States
🇺🇸Rush-Presbytarian-St Luke's Medical Center, Chicago, Illinois, United States
HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)
- Conditions
- HIV-Associated Lipodystrophy SyndromeCardiovascular Disease
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2012-04-12
- Lead Sponsor
- Kirby Institute
- Target Recruit Count
- 80
- Registration Number
- NCT00192660
- Locations
- 🇦🇺
St. Vincent's Hospital, Sydney, New South Wales, Australia
Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected Subjects
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2014-03-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 997
- Registration Number
- NCT00146328
- Locations
- 🇺🇸
1182.17.26 Boehringer Ingelheim Investigational Site, Columbus, Ohio, United States
🇺🇸1182.17.89 Boehringer Ingelheim Investigational Site, Berkeley, California, United States
🇺🇸1182.17.73 Boehringer Ingelheim Investigational Site, Los Angeles, California, United States
Tipranavir Expanded Access Program (EAP) in PI-experienced Patients With HIV-1 Infection
- Conditions
- HIV Infections
- First Posted Date
- 2004-12-01
- Last Posted Date
- 2016-11-30
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT00097799
- Locations
- 🇺🇸
1182.70.066, Los Angeles, California, United States
🇺🇸1182.70.174, Macon, Georgia, United States
🇺🇸1182.70.071, Los Angeles, California, United States
Tipranavir in Patients With Progressive, Systemic HIV-1 Disease Who Have Failed or Are Intolerant to Currently Approved Treatments for HIV Infection
- Conditions
- HIV Infections
- First Posted Date
- 2003-06-12
- Last Posted Date
- 2016-11-30
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT00062660
- Locations
- 🇺🇸
1182.58.20 University of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸1182.58.18 University of Texas Southwest Medical Center at Dallas, Dallas, Texas, United States
🇦🇺1182.58.61012 Bigge Park Centre, Liverpool, New South Wales, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.